| 摘要 |
The disclosure concerns novel 1-benzyl-1,2,3,6-tetrahydropyridine derivatives of the formula: <IMAGE> I wherein R1 is hydrogen or a (1-4C)-alkyl radical, and benzene ring A bears one or two substituents selected from combinations of halogeno, (1-4C)-alkyl, (1-4C)-alkoxy, hydroxy, nitro, cyano, carboxamido, carboxyl, [(1-4C)-alkoxy]carbonyl, hydroxymethylene, amino, (1-4C)-alkanoylamino, (1-4C)-alkylsulphonamido, [(1-4C)-alkoxy]carbonyloxy, (1-4C)-alkanoyloxy and optionally substituted benzoyloxy radicals, and their pharmaceutically acceptable salts; pharmaceutical compositions thereof; analogy processes for their manufacture; and methods of medical treatment employing such derivatives. The compounds of formula I are inhibitors of the aggregation of blood platelets and are of application in the treatment or prophylaxis of thrombosis or occlusive vascular disease. Representative compounds possessing particularly good blood platelet aggregation inhibitory properties are 1-(3,4-dichloro-, 4-chloro-3-hydroxy-, and 4-hydroxy-benzyl)-1,2,3,6-tetrahydropyridine, preferably as their hydrochloride salts. |
